TNNT2

Summary

TNNT2 (troponin T2, cardiac type, HGNC:11949) is a protein-coding gene on chromosome 1q32.1, encoding Troponin T, cardiac muscle (P45379). Troponin T is the tropomyosin-binding subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. It is a selective cancer dependency (DepMap: 27.1% of cell lines).

This gene encodes the cardiac isoform of troponin T. The encoded protein is the tropomyosin-binding subunit of the troponin complex, which is located on the thin filament of striated muscles and regulates muscle contraction in response to alterations in intracellular calcium ion concentration. Mutations in this gene have been associated with familial hypertrophic cardiomyopathy as well as with dilated cardiomyopathy.

Source: NCBI Gene 7139 — RefSeq curated summary.

At a glance

• Gene–disease (curated): dilated cardiomyopathy 1D (Definitive, ClinGen) — +9 more curated relationships
• GWAS associations: 6
• Clinical variants (ClinVar): 1,152 total — 14 pathogenic, 32 likely-pathogenic
• Phenotypes (HPO): 57
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 27.1% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001276345

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11949
Approved symbol	TNNT2
Name	troponin T2, cardiac type
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	CMPD2
Ensembl gene	ENSG00000118194
Ensembl biotype	protein_coding
OMIM	191045
Entrez	7139

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 25 protein_coding, 7 retained_intron, 5 protein_coding_CDS_not_defined, 4 nonsense_mediated_decay

ENST00000367318, ENST00000367320, ENST00000367322, ENST00000412633, ENST00000422165, ENST00000438742, ENST00000445079, ENST00000455702, ENST00000460780, ENST00000466570, ENST00000472177, ENST00000475686, ENST00000476888, ENST00000477035, ENST00000491504, ENST00000494095, ENST00000503459, ENST00000509001, ENST00000515042, ENST00000651504, ENST00000656932, ENST00000658476, ENST00000660295, ENST00000662159, ENST00000663843, ENST00000666449, ENST00000714312, ENST00000714313, ENST00000714314, ENST00000714315, ENST00000714316, ENST00000714317, ENST00000961996, ENST00000961997, ENST00000961998, ENST00000961999, ENST00000962000, ENST00000962001, ENST00000962002, ENST00000962003, ENST00000962004

RefSeq mRNA: 13 — MANE Select: NM_001276345 NM_000364, NM_001001430, NM_001001431, NM_001001432, NM_001276345, NM_001276346, NM_001276347, NM_001406723, NM_001406724, NM_001406725, NM_001406726, NM_001406727, NM_001406728

CCDS: CCDS30968, CCDS30969, CCDS60390, CCDS73003

Canonical transcript exons

ENST00000656932 — 17 exons

Exon	Start	End
ENSE00001444197	201369816	201369845
ENSE00001444204	201377623	201377680
ENSE00003467518	201373214	201373268
ENSE00003488921	201361279	201361369
ENSE00003514510	201365610	201365670
ENSE00003520322	201368162	201368227
ENSE00003523427	201363296	201363406
ENSE00003554410	201372027	201372041
ENSE00003613333	201367771	201367806
ENSE00003660777	201365191	201365307
ENSE00003661906	201372145	201372155
ENSE00003666033	201361913	201362022
ENSE00003685555	201362386	201362394
ENSE00003686160	201364298	201364375
ENSE00003718704	201366838	201366871
ENSE00003877901	201359623	201359663
ENSE00004023534	201359014	201359255

Expression profiles

Bgee: expression breadth ubiquitous, 154 present calls, max score 99.96.

FANTOM5 (CAGE): breadth broad, TPM avg 57.5413 / max 13317.6984, expressed in 381 samples.

FANTOM5 promoters (15 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16637	56.1636	370
16633	0.3618	47
16634	0.2962	48
16627	0.1113	32
16631	0.1093	27
16623	0.0905	25
16626	0.0801	30
16635	0.0571	15
16622	0.0506	15
16624	0.0505	21

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.96	gold quality
right atrium auricular region	UBERON:0006631	99.95	gold quality
cardiac atrium	UBERON:0002081	99.09	gold quality
heart left ventricle	UBERON:0002084	98.38	gold quality
cardiac ventricle	UBERON:0002082	97.28	gold quality
sural nerve	UBERON:0015488	97.12	gold quality
heart	UBERON:0000948	94.67	gold quality
right frontal lobe	UBERON:0002810	91.72	gold quality
tibial nerve	UBERON:0001323	90.90	gold quality
lower esophagus mucosa	UBERON:0035834	90.60	gold quality
skin of leg	UBERON:0001511	90.01	gold quality
skin of abdomen	UBERON:0001416	89.70	gold quality
Brodmann (1909) area 9	UBERON:0013540	89.70	gold quality
anterior cingulate cortex	UBERON:0009835	88.33	gold quality
right lung	UBERON:0002167	85.50	gold quality
zone of skin	UBERON:0000014	84.65	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	84.40	gold quality
upper lobe of left lung	UBERON:0008952	83.56	gold quality
adult mammalian kidney	UBERON:0000082	82.65	gold quality
gastrocnemius	UBERON:0001388	82.37	gold quality
metanephros cortex	UBERON:0010533	82.21	gold quality
prefrontal cortex	UBERON:0000451	81.64	gold quality
right coronary artery	UBERON:0001625	80.81	gold quality
upper lobe of lung	UBERON:0008948	80.76	gold quality
muscle of leg	UBERON:0001383	80.64	gold quality
esophagus mucosa	UBERON:0002469	79.93	gold quality
neocortex	UBERON:0001950	78.90	gold quality
frontal cortex	UBERON:0001870	78.55	gold quality
left coronary artery	UBERON:0001626	77.26	gold quality
coronary artery	UBERON:0001621	76.36	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	18.84
E-MTAB-11268	no	4885.32
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ARRB2, GSK3B, HBP1, MEF2A, PARP1, SP1, SP3, TEAD1

miRNA regulators (miRDB)

12 targeting TNNT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-12132	99.47	68.90	1341
HSA-MIR-3911	99.38	66.95	1087
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-10398-5P	97.12	64.94	1051

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 27.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• Frataxin and cardiac troponin T gene mutations co-exist in a child with Friedreich ataxia and familial hypertrophic cardiomyopathy. (PMID:11857753)
• functional slow skeletal muscle troponin T requires a full, non-truncated sequence including the COOH-terminal domain (PMID:12732643)
• It was concluded that myoglobin levels on admission and TnT at 2 h had the greatest diagnostic rate for myocardial infarction. (PMID:12760310)
• Data suggest that apoptosis signal-regulating kinase 1 plays an important role in regulation of cardiac contractile function by phosphorylating cardiac troponin T2. (PMID:12819028)
• effects of Troponin T (TnT) mutants R141W and DeltaK210 on the Ca2+ sensitivity of force development in cardiac fibers and maximal ATPase activity (PMID:12923187)
• different regions of TnT may contribute to the pathogenesis of TnT-linked Familial hypertrophic cardiomyopathy through different mechanisms (PMID:14722098)
• TNNT2 deletion allele could be associated with a predisposition to prominent left ventricular hypertrophy (PMID:14986170)
• Quantitative test is useful for early diagnosis of acute myocardial infarct and as an indicator of its severity. (PMID:15226628)
• slow skeletal TnT mRNA is readily detectable during early human heart development (PMID:15524170)
• Role of TnT in muscle physiology and disease. Review. (PMID:15524172)
• Evidence is shown that the Delta14 mutation of troponin T, as seen in some cases of familial hypertrophic cardiomyopathy, results in stabilization of regulated actin in a more active state. (PMID:15568820)
• NT-proBNP, cTnT, or cTnI do not have roles in acute ischemic stroke when other risk factors are considered (PMID:15604421)
• Measurement of the serum levels of cTnT is of clinical importance in evaluating myocardial injury (PMID:15673967)
• No differences in troponin T or inotropic support levels found in relation to modality of organ donors’ brain death. (PMID:15759546)
• Cardiac troponin T may have a role in progression of atherosclerosis (PMID:15950076)
• Troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers (PMID:16115869)
• Increases after exercise in athletes (PMID:16338248)
• infantile case of restrictive cardiomyopathy caused by a de novo mutation of the cardiac troponin T gene. (PMID:16651346)
• Elevated cardiac troponin T may be an early marker of overall disease severity and a predictor of outcome. (PMID:16716613)
• at-birth reference values previously established for cTnT and amino-terminal pro-natriuretic peptide (PMID:16776629)
• In transgenic rats expressing a TnT truncation as models of human familial hypertrophic cardiomyopathy, the force-generating capacity of cycling cross-bridges is impaired, resulting in increased tension-dependent ATP utilization. (PMID:16882671)
• spectrum of mutations in cardiac hypertrophy patients (PMID:17101185)
• serum troponin T concentrations were not elevated in healthy professional football players with left ventricular hypertrophy (LVH); this argues against the hypothesis that LVH per se may cause increased cTnT (PMID:17289431)
• Intact cTnT rapidly disappears from the circulation during the early hours after acute myocardial infarction, but immunoreactive fragments remain present longer. (PMID:17512511)
• a positive correlation between age and interventricular septal thickness for South African R92W(TNNT2) families (PMID:17612745)
• validated occurrence of an unusual TG 3’ splice site in intron 1 (PMID:17672918)
• Troponin T has a role in rat myocardial infarction induced by isoproterenol (PMID:17848144)
• A single NT-pro BNP and cTnT value at 96 hours after onset of symptoms proved useful for estimation of left ventricular ejection fraction and infarct size. (PMID:17891611)
• Troponin T mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. (PMID:18029407)
• chronic obstructive pulmonary disease patients with elevated cardiac-specific Troponin T during exacerbation are at increased risk of death after discharge. (PMID:18032444)
• N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) level strongly correlates with left ventricular systolic dysfunction and is associated more strongly with mortality than cTnT level in asymptomatic hemodialysis patients. (PMID:18037101)
• Review hypothesizes that increased serum cardiac troponin T concentrations during chronic compensated heart failure identify patients likely to need multiple admissions to the hospital for management of acute cardiac decompensation. (PMID:18063145)
• Elevated Troponin T level is a strong independent predictor of all cause mortality in patients with a renal transplant. (PMID:18065785)
• Troponin T elevations occurred in all patients undergoing pulmonary vein isolation, to levels at least 20 times the normal concentration, into the range for diagnosis of acute myocardial infarction. (PMID:18174208)
• There was a significant inverse correlation between cTnT (cardiac troponin T) and echocardiographic markers of myocardial function and stroke volume in preterm infants (PMID:18322550)
• troponin T is a more specific marker than H-FABP (heart-type fatty acid binding protein) of acute Myocardial Infarct in patients presenting with chest pain (PMID:18460953)
• Nine distinct mutations, 7 of them in MYH7, 1 in ACTC, and 1 in TNNT2, were found unrelated adult probands with left ventricular noncompaction and no other congenital heart anomalies (PMID:18506004)
• Baseline elevation of cTn is relatively common among patients with stable coronary artery disease undergoing percutaneous intervention and is an independent prognostic indicator of ischemic complications (PMID:18645057)
• Sequencing of TNNT2 identified a heterozygous missense mutation resulting in an I79N substitution in familial cardiomyopathy with variable remodeling and restrictive physiology. (PMID:18651846)
• cTnT may be an aid in risk stratification of continuous ambulatory peritoneal dialysis patients for cardiovascular disease (PMID:18719346)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	tnnt2a	ENSDARG00000020610
danio_rerio	tnnt2b	ENSDARG00000100694
mus_musculus	Tnnt2	ENSMUSG00000026414
rattus_norvegicus	Tnnt2	ENSRNOG00000033734
drosophila_melanogaster	up	FBGN0004169
caenorhabditis_elegans		WBGENE00006588

Paralogs (2): TNNT1 (ENSG00000105048), TNNT3 (ENSG00000130595)

Protein

Protein identifiers

Troponin T, cardiac muscle — P45379 (reviewed: P45379)

Alternative names: Cardiac muscle troponin T

All UniProt accessions (12): A0A499FJM7, A0A590UJV2, A0A590UK21, A0A590UK91, A0A590UKC2, A0AAQ5BHV8, A0AAQ5BHV9, A0AAQ5BHW1, A0AAQ5BHX3, P45379, E7EPN8, E7EPW4

UniProt curated annotations — full annotation on UniProt →

Function. Troponin T is the tropomyosin-binding subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.

Tissue specificity. Heart. The fetal heart shows a greater expression in the atrium than in the ventricle, while the adult heart shows a greater expression in the ventricle than in the atrium. Isoform 6 predominates in normal adult heart. Isoforms 1, 7 and 8 are expressed in fetal heart. Isoform 7 is also expressed in failing adult heart.

Post-translational modifications. Phosphorylation at Thr-213 by PRKCA induces significant reduction in myofilament calcium sensitivity and actomyosin ATPase activity.

Disease relevance. Cardiomyopathy, familial hypertrophic, 2 (CMH2) [MIM:115195] A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. The disease is caused by variants affecting the gene represented in this entry. Cardiomyopathy, dilated, 1D (CMD1D) [MIM:601494] A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. The disease is caused by variants affecting the gene represented in this entry. Cardiomyopathy, familial restrictive 3 (RCM3) [MIM:612422] A heart disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the troponin T family.

Isoforms (12)

UniProt ID	Names	Canonical?
P45379-1	1, TNT1	yes
P45379-2	2
P45379-3	3
P45379-4	4
P45379-5	5
P45379-6	6, TNT3
P45379-7	7, TNT4
P45379-8	8, TNT2
P45379-9	9
P45379-10	10
P45379-11	11
P45379-12	12

RefSeq proteins (13): NP_000355, NP_001001430, NP_001001431, NP_001001432, NP_001263274, NP_001263275, NP_001263276, NP_001393652, NP_001393653, NP_001393654, NP_001393655, NP_001393656, NP_001393657 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001978	Troponin	Family
IPR027707	TNNT	Family
IPR038077	Troponin_sf	Homologous_superfamily

Pfam: PF00992

UniProt features (55 total): sequence variant 31, splice variant 8, modified residue 6, compositionally biased region 3, region of interest 2, helix 2, initiator methionine 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

25 structures.

PDB	Method	Resolution (Å)
4Y99	X-RAY DIFFRACTION	2
1J1D	X-RAY DIFFRACTION	2.61
8FMO	X-RAY DIFFRACTION	2.61
8FMT	X-RAY DIFFRACTION	2.8
8FMN	X-RAY DIFFRACTION	3.1
8FMM	X-RAY DIFFRACTION	3.11
8FMR	X-RAY DIFFRACTION	3.24
8FMP	X-RAY DIFFRACTION	3.24
8FMQ	X-RAY DIFFRACTION	3.25
1J1E	X-RAY DIFFRACTION	3.3
8FMS	X-RAY DIFFRACTION	3.44
6KN8	ELECTRON MICROSCOPY	4.8
7UTI	ELECTRON MICROSCOPY	4.8
9MOW	ELECTRON MICROSCOPY	4.9
9MOP	ELECTRON MICROSCOPY	5
9MOO	ELECTRON MICROSCOPY	5.2
9MOX	ELECTRON MICROSCOPY	5.2
9MOA	ELECTRON MICROSCOPY	5.4
9MOB	ELECTRON MICROSCOPY	5.5
9MO9	ELECTRON MICROSCOPY	5.6
9MOC	ELECTRON MICROSCOPY	5.6
9MOU	ELECTRON MICROSCOPY	5.6
9MOD	ELECTRON MICROSCOPY	5.7
6KN7	ELECTRON MICROSCOPY	6.6
7UTL	ELECTRON MICROSCOPY	6.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P45379-F1	78.93	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 208, 213, 294, 2, 2, 204

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-390522	Striated Muscle Contraction

MSigDB gene sets: 323 (showing top): GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_CARDIAC_CHAMBER_MORPHOGENESIS, GOBP_NEGATIVE_REGULATION_OF_ATP_DEPENDENT_ACTIVITY, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, AP4_Q6, MEF2_02, GOBP_SARCOMERE_ORGANIZATION, CAGCTG_AP4_Q5, GNF2_MYL3, GOBP_RESPONSE_TO_METAL_ION, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, GOBP_ANIMAL_ORGAN_MORPHOGENESIS

GO Biological Process (10): regulation of muscle contraction (GO:0006937), regulation of heart contraction (GO:0008016), muscle filament sliding (GO:0030049), negative regulation of ATP-dependent activity (GO:0032780), positive regulation of ATP-dependent activity (GO:0032781), sarcomere organization (GO:0045214), response to calcium ion (GO:0051592), ventricular cardiac muscle tissue morphogenesis (GO:0055010), cardiac muscle contraction (GO:0060048), striated muscle contraction (GO:0006941)

GO Molecular Function (7): actin binding (GO:0003779), tropomyosin binding (GO:0005523), troponin C binding (GO:0030172), troponin I binding (GO:0031013), identical protein binding (GO:0042802), microfilament motor activity (GO:0000146), protein binding (GO:0005515)

GO Cellular Component (6): cytosol (GO:0005829), troponin complex (GO:0005861), striated muscle thin filament (GO:0005865), sarcomere (GO:0030017), cardiac myofibril (GO:0097512), cardiac Troponin complex (GO:1990584)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoskeletal protein binding	4
muscle contraction	3
ATP-dependent activity	3
heart contraction	2
regulation of ATP-dependent activity	2
cellular anatomical structure	2
myofibril	2
regulation of muscle system process	1
regulation of blood circulation	1
actin-myosin filament sliding	1
negative regulation of molecular function	1
positive regulation of molecular function	1
myofibril assembly	1
actomyosin structure organization	1
response to metal ion	1
cardiac ventricle morphogenesis	1
ventricular cardiac muscle tissue development	1
cardiac muscle tissue morphogenesis	1
striated muscle contraction	1
protein binding	1
cytoskeletal motor activity	1
polypeptide conformation or assembly isomerase activity	1
binding	1
cytoplasm	1
striated muscle thin filament	1
protein-containing complex	1
actin cytoskeleton	1
sarcomere	1
myofilament	1
troponin complex	1

Protein interactions and networks

STRING

1919 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TNNT2	TNNI3	P19429	999
TNNT2	MYBPC3	Q14896	972
TNNT2	TPM1	P09493	969
TNNT2	MYH7	P12883	957
TNNT2	ACTC1	P04270	943
TNNT2	TNNC1	P02590	916
TNNT2	TNNI1	P19237	909
TNNT2	NKX2-5	P52952	903
TNNT2	MYH6	P13533	900
TNNT2	MYL3	P08590	886
TNNT2	MYL2	P10916	877
TNNT2	ACTN2	P35609	866
TNNT2	LDB3	O75112	857
TNNT2	TNNI2	P48788	856
TNNT2	CELF2	O95319	849

IntAct

7 interactions, top by confidence:

A	B	Type	Score
TNNC1	TNNI3	psi-mi:“MI:0915”(physical association)	0.670
TNNT2	MORF4L2	psi-mi:“MI:0915”(physical association)	0.560
TNNT2	KDM1A	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (18): MORF4L2 (Two-hybrid), TNNT2 (Reconstituted Complex), TNNT2 (Biochemical Activity), TNNT2 (Reconstituted Complex), TNNT2 (Two-hybrid), TNNT2 (Two-hybrid), TNNT2 (Two-hybrid), TNNT2 (Two-hybrid), TNNT2 (Two-hybrid), TNNI1 (Two-hybrid), MORF4L1 (Two-hybrid), TRIM69 (Two-hybrid), TNNT2 (Reconstituted Complex), TNNT2 (Reconstituted Complex), TNNT2 (Two-hybrid)

ESM2 similar proteins: A4IFB1, A5D7A0, O88346, P02641, P02642, P02646, P06398, P08057, P09739, P09741, P12620, P13789, P13805, P19351, P19429, P23693, P45378, P45379, P48787, P50751, P50752, P50753, P50754, P68246, P68247, P92948, Q13435, Q27371, Q28HN4, Q2KIT1, Q2TBV6, Q39604, Q3UJB0, Q4FZY0, Q5PYI0, Q6DD17, Q75NG9, Q75ZZ6, Q7TNB2, Q863B6

Diamond homologs: O88346, P02641, P02642, P06398, P09739, P09741, P12620, P13789, P13805, P19351, P45378, P45379, P50751, P50752, P50753, Q75NG9, Q75ZZ6, Q7TNB2, Q8MKH6, Q8MKI3, Q9QZ47, Q9XZ71, Q27371

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
“MYOD1/SWI/SNF complex”	“up-regulates quantity by expression”	TNNT2	“transcriptional regulation”
CELF4	“up-regulates quantity”	TNNT2	“post transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

1152 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	14
Likely pathogenic	32
Uncertain significance	514
Likely benign	360
Benign	63

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
12408	NM_001276345.2(TNNT2):c.266T>A (p.Ile89Asn)	Pathogenic
12412	NM_001276345.2(TNNT2):c.358T>A (p.Phe120Ile)	Pathogenic
12416	NM_001276345.2(TNNT2):c.644G>T (p.Arg215Leu)	Pathogenic
181639	NM_001276345.2(TNNT2):c.844dup (p.Gln282fs)	Pathogenic
181641	NM_001276345.2(TNNT2):c.269C>T (p.Pro90Leu)	Pathogenic
2100789	NM_001276345.2(TNNT2):c.321G>C (p.Lys107Asn)	Pathogenic
228409	NM_001276345.2(TNNT2):c.547C>T (p.Arg183Trp)	Pathogenic
235063	NM_001276345.2(TNNT2):c.305G>T (p.Arg102Leu)	Pathogenic
2500774	NM_001276345.2(TNNT2):c.310C>A (p.Arg104Ser)	Pathogenic
3753583	NM_001276345.2(TNNT2):c.291T>G (p.Phe97Leu)	Pathogenic
431937	NM_001276345.2(TNNT2):c.847A>G (p.Lys283Glu)	Pathogenic
43637	NM_001276345.2(TNNT2):c.422G>A (p.Arg141Gln)	Pathogenic
684850	NM_001276345.2(TNNT2):c.328_333del (p.Asn110_Glu111del)	Pathogenic
691967	NM_001276345.2(TNNT2):c.548G>T (p.Arg183Leu)	Pathogenic
1319259	NM_001276345.2(TNNT2):c.499G>C (p.Ala167Pro)	Likely pathogenic
1435754	NM_001276345.2(TNNT2):c.283G>A (p.Val95Met)	Likely pathogenic
1699339	NM_001276345.2(TNNT2):c.299T>A (p.Ile100Asn)	Likely pathogenic
1701922	NM_001276345.2(TNNT2):c.68-2A>G	Likely pathogenic
177636	NM_001276345.2(TNNT2):c.890G>A (p.Trp297Ter)	Likely pathogenic
177855	NM_001276345.2(TNNT2):c.837C>A (p.Asn279Lys)	Likely pathogenic
181622	NM_001276345.2(TNNT2):c.526A>G (p.Arg176Gly)	Likely pathogenic
2115456	NM_001276345.2(TNNT2):c.445C>G (p.Arg149Gly)	Likely pathogenic
217496	NM_001276345.2(TNNT2):c.662T>C (p.Ile221Thr)	Likely pathogenic
2202921	NM_001276345.2(TNNT2):c.290T>A (p.Phe97Tyr)	Likely pathogenic
235064	NM_001276345.2(TNNT2):c.358T>C (p.Phe120Leu)	Likely pathogenic
2444397	NM_001276345.2(TNNT2):c.609+2T>A	Likely pathogenic
2505116	NM_001276345.2(TNNT2):c.652A>G (p.Lys218Glu)	Likely pathogenic
2505127	NM_001276345.2(TNNT2):c.630G>C (p.Lys210Asn)	Likely pathogenic
2942386	NM_001276345.2(TNNT2):c.304C>G (p.Arg102Gly)	Likely pathogenic
3337677	NM_001276345.2(TNNT2):c.452G>T (p.Arg151Leu)	Likely pathogenic

SpliceAI

2734 predictions. Top by Δscore:

Variant	Effect	Δscore
1:201359621:A:AC	donor_gain	1.0000
1:201359622:C:CC	donor_gain	1.0000
1:201359622:CA:C	donor_gain	1.0000
1:201361365:TCTCC:T	acceptor_gain	1.0000
1:201361366:CTCC:C	acceptor_gain	1.0000
1:201361366:CTCCC:C	acceptor_gain	1.0000
1:201361367:TCC:T	acceptor_gain	1.0000
1:201361367:TCCCT:T	acceptor_gain	1.0000
1:201361368:CC:C	acceptor_gain	1.0000
1:201361368:CCC:C	acceptor_gain	1.0000
1:201361369:CC:C	acceptor_gain	1.0000
1:201361369:CCT:C	acceptor_loss	1.0000
1:201361370:C:CC	acceptor_gain	1.0000
1:201361373:C:CT	acceptor_gain	1.0000
1:201361379:C:CT	acceptor_gain	1.0000
1:201361380:A:T	acceptor_gain	1.0000
1:201361917:G:C	donor_gain	1.0000
1:201361922:T:C	donor_gain	1.0000
1:201361953:T:A	donor_gain	1.0000
1:201362019:CTGT:C	acceptor_gain	1.0000
1:201362020:TGT:T	acceptor_gain	1.0000
1:201362023:C:CC	acceptor_gain	1.0000
1:201362030:G:C	acceptor_gain	1.0000
1:201362030:G:GC	acceptor_gain	1.0000
1:201362032:G:C	acceptor_gain	1.0000
1:201363403:CTTC:C	acceptor_gain	1.0000
1:201363404:TTCC:T	acceptor_loss	1.0000
1:201363405:TC:T	acceptor_gain	1.0000
1:201363405:TCCTG:T	acceptor_loss	1.0000
1:201363406:CC:C	acceptor_gain	1.0000

AlphaMissense

2004 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:201359643:C:A	R277S	0.999
1:201359643:C:G	R277S	0.999
1:201359650:C:G	R275P	0.999
1:201359653:A:G	L274P	0.999
1:201361310:A:G	L260P	0.999
1:201361315:G:C	F258L	0.999
1:201361315:G:T	F258L	0.999
1:201361317:A:G	F258L	0.999
1:201361362:C:G	A243P	0.999
1:201365242:A:C	F120L	0.999
1:201365242:A:T	F120L	0.999
1:201365244:A:G	F120L	0.999
1:201365267:A:G	L112S	0.999
1:201359644:C:A	R277M	0.998
1:201359645:T:C	R277G	0.998
1:201361289:T:G	Q267P	0.998
1:201361326:C:G	A255P	0.998
1:201361352:A:G	L246P	0.998
1:201361916:A:G	L239P	0.998
1:201361957:C:A	R225S	0.998
1:201361957:C:G	R225S	0.998
1:201361978:C:A	K218N	0.998
1:201361978:C:G	K218N	0.998
1:201361988:C:G	R215P	0.998
1:201363344:C:A	K184N	0.998
1:201363344:C:G	K184N	0.998
1:201365233:C:A	R123S	0.998
1:201365233:C:G	R123S	0.998
1:201365247:G:C	H119D	0.998
1:201365258:A:G	L115P	0.998

dbSNP variants (sampled 300 via entrez): RS1000032303 (1:201378389 G>A,T), RS1000291382 (1:201375394 G>A), RS1000341399 (1:201376506 T>TGGGGAGAGGGC), RS1000348301 (1:201376894 A>C,G), RS1000817161 (1:201365165 G>A), RS1000881331 (1:201366137 G>A), RS1000921827 (1:201365419 C>A,T), RS1000975795 (1:201360385 A>G,T), RS1001073027 (1:201377040 G>A), RS1001142745 (1:201371022 C>T), RS1001308898 (1:201371203 G>T), RS1001450913 (1:201376485 A>T), RS1001814242 (1:201368747 T>TAGAA), RS1001962475 (1:201374154 A>G), RS1002280667 (1:201365044 A>G)

Disease associations

OMIM: gene MIM:191045 | disease phenotypes: MIM:115195, MIM:601494, MIM:612422, MIM:192600, MIM:218040, MIM:613172, MIM:115200, MIM:604169, MIM:115197, MIM:613426, MIM:242300, MIM:194200, MIM:613690

GenCC curated gene-disease

Disease	Classification	Inheritance
hypertrophic cardiomyopathy 2	Definitive	Autosomal dominant
dilated cardiomyopathy 1D	Definitive	Autosomal dominant
hypertrophic cardiomyopathy 3	Definitive	Autosomal dominant
cardiomyopathy, familial restrictive, 3	Strong	Autosomal dominant
familial isolated dilated cardiomyopathy	Supportive	Autosomal dominant
left ventricular noncompaction	Supportive	Autosomal dominant
familial isolated restrictive cardiomyopathy	Supportive	Autosomal dominant
cardiomyopathy	Limited	Autosomal recessive
arrhythmogenic right ventricular cardiomyopathy	No Known Disease Relationship	Autosomal dominant

ClinGen Gene-Disease Validity (3)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
dilated cardiomyopathy 1D	Definitive	AD
arrhythmogenic right ventricular cardiomyopathy	No Known Disease Relationship	AD
hypertrophic cardiomyopathy	Moderate	AD

Mondo (24): cardiomyopathy (MONDO:0004994), hypertrophic cardiomyopathy 2 (MONDO:0007266), dilated cardiomyopathy 1D (MONDO:0011095), cardiomyopathy, familial restrictive, 3 (MONDO:0012900), hypertrophic cardiomyopathy (MONDO:0005045), hypertrophic cardiomyopathy 1 (MONDO:0008647), Costello syndrome (MONDO:0009026), dilated cardiomyopathy (MONDO:0005021), familial isolated dilated cardiomyopathy (MONDO:0700335), dilated cardiomyopathy 1DD (MONDO:0013168), myocarditis (MONDO:0004496), familial hypertrophic cardiomyopathy (MONDO:0024573), restrictive cardiomyopathy (MONDO:0005201), familial dilated cardiomyopathy (MONDO:0016333), left ventricular noncompaction (MONDO:0018901)

Orphanet (12): Familial isolated dilated cardiomyopathy (Orphanet:154), Rare cardiomyopathy (Orphanet:167848), Left ventricular noncompaction (Orphanet:54260), Familial isolated restrictive cardiomyopathy (Orphanet:75249), Rare hypertrophic cardiomyopathy (Orphanet:217569), Costello syndrome (Orphanet:3071), Dilated cardiomyopathy (Orphanet:217604), Rare familial disorder with hypertrophic cardiomyopathy (Orphanet:99739), Restrictive cardiomyopathy (Orphanet:217632), Familial dilated cardiomyopathy (Orphanet:217607), NON RARE IN EUROPE: Familial isolated hypertrophic cardiomyopathy (Orphanet:155), NON RARE IN EUROPE: Wolff-Parkinson-White syndrome (Orphanet:907)

HPO phenotypes

57 total (30 of 57 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000407	Sensorineural hearing impairment
HP:0000969	Edema
HP:0001279	Syncope
HP:0001297	Stroke
HP:0001635	Congestive heart failure
HP:0001639	Hypertrophic cardiomyopathy
HP:0001644	Dilated cardiomyopathy
HP:0001645	Sudden cardiac death
HP:0001653	Mitral regurgitation
HP:0001657	Prolonged QT interval
HP:0001681	Angina pectoris
HP:0001688	Sinus bradycardia
HP:0001712	Left ventricular hypertrophy
HP:0001723	Restrictive cardiomyopathy
HP:0001727	Thromboembolic stroke
HP:0001907	Thromboembolism
HP:0002094	Dyspnea
HP:0002205	Recurrent respiratory infections
HP:0002240	Hepatomegaly
HP:0002615	Hypotension
HP:0002875	Exertional dyspnea
HP:0003198	Myopathy
HP:0003457	EMG abnormality
HP:0003593	Infantile onset
HP:0003596	Middle age onset
HP:0003621	Juvenile onset
HP:0004942	Aortic aneurysm
HP:0005110	Atrial fibrillation
HP:0005115	Supraventricular arrhythmia

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001776_10	Cardiac Troponin-T levels	5.000000e-08
GCST002594_18	Neurofibrillary tangles	9.000000e-06
GCST008163_18	Height	4.000000e-06
GCST010796_4828	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_4829	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_4830	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005043	cardiac troponin T measurement
EFO:0006797	neurofibrillary tangles measurement
EFO:0004327	electrocardiography

MeSH disease descriptors (18)

Descriptor	Name	Tree numbers
D019571	Arrhythmogenic Right Ventricular Dysplasia	C14.240.400.145; C14.280.238.028; C14.280.400.145; C16.131.240.400.145
D009202	Cardiomyopathies	C14.280.238
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
D024741	Cardiomyopathy, Hypertrophic, Familial	C14.280.238.100.500; C14.280.484.048.750.070.160.500; C16.320.160
D002313	Cardiomyopathy, Restrictive	C14.280.238.160
D056685	Costello Syndrome	C05.660.207.219; C16.131.077.256; C16.320.188
D017490	Ichthyosis, Lamellar	C16.131.831.512.400.410; C16.320.850.400.410; C16.614.492.400.410; C17.800.428.333.250.410; C17.800.804.512.400.410; C17.800.827.400.410
D009205	Myocarditis	C14.280.238.625
D014927	Wolff-Parkinson-White Syndrome	C14.280.067.780.977; C14.280.123.750.977; C16.131.240.400.980
C563306	Cardiomyopathy, Dilated, 1D (supp.)
C567725	Cardiomyopathy, Dilated, 1DD (supp.)
C563538	Cardiomyopathy, Dilated, 1s (supp.)
C566171	Cardiomyopathy, Familial Hypertrophic, 2 (supp.)
C566170	Cardiomyopathy, Familial Hypertrophic, 3 (supp.)
C566169	Cardiomyopathy, Familial Hypertrophic, 4 (supp.)
C567316	Cardiomyopathy, Familial Restrictive, 3 (supp.)
C536231	familial dilated cardiomyopathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2095202 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

81 potent at pChembl≥5 of 118 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.78	EC50	164.6	nM	CHEMBL3195681
6.78	EC50	165.1	nM	CHEMBL1581326
6.72	EC50	190.7	nM	CHEMBL3195851
6.55	EC50	278.9	nM	CHEMBL1468444
6.54	EC50	286.9	nM	CHEMBL1379673
6.40	EC50	397	nM	CHEMBL1477915
6.38	EC50	413	nM	CHEMBL1398812
6.30	EC50	500.5	nM	CHEMBL1369691
6.29	EC50	515.8	nM	CHEMBL1573529
6.25	IC50	558.1	nM	PYROGALLOL RED
6.25	EC50	565.4	nM	CHEMBL3197404
6.21	EC50	615.4	nM	CHEMBL1388372
6.17	IC50	676.8	nM	CHEMBL1425538
6.13	EC50	742	nM	CHEMBL1604510
6.12	EC50	760.7	nM	CHEMBL1550816
6.07	EC50	852.9	nM	CHEMBL1725987
6.06	EC50	869.6	nM	CHEMBL1586687
5.96	EC50	1101	nM	CHEMBL1975147
5.95	EC50	1113	nM	CHEMBL1313968
5.94	EC50	1143	nM	CHEMBL1429070
5.94	EC50	1137	nM	CHEMBL1310204
5.92	EC50	1209	nM	CHEMBL1713654
5.86	EC50	1369	nM	CHEMBL1501273
5.84	EC50	1438	nM	CHEMBL1977499
5.83	EC50	1465	nM	CHEMBL1499258
5.81	EC50	1537	nM	CHEMBL1542169
5.81	EC50	1548	nM	CHEMBL1574521
5.80	EC50	1577	nM	CHEMBL1407632
5.79	IC50	1640	nM	CHEMBL1563898
5.74	IC50	1819	nM	CHEMBL1356785
5.74	EC50	1830	nM	CHEMBL1586067
5.73	EC50	1863	nM	CHEMBL1971695
5.73	EC50	1878	nM	CHEMBL1576905
5.70	EC50	1981	nM	CHEMBL1701437
5.69	EC50	2022	nM	CHEMBL1466913
5.66	EC50	2177	nM	CHEMBL1576602
5.65	EC50	2218	nM	CHEMBL1462008
5.62	EC50	2385	nM	CHEMBL1540557
5.59	EC50	2576	nM	CHEMBL1466606
5.59	EC50	2574	nM	CHEMBL1725983
5.57	IC50	2724	nM	CHEMBL1362935
5.57	EC50	2706	nM	CHEMBL1557186
5.56	EC50	2780	nM	CHEMBL2004884
5.54	EC50	2901	nM	CHEMBL1547468
5.54	EC50	2918	nM	CHEMBL1311198
5.50	IC50	3191	nM	CHEMBL1601846
5.48	EC50	3326	nM	CHEMBL1596655
5.46	IC50	3446	nM	CHEMBL1424694
5.44	IC50	3615	nM	PURPUROGALLIN
5.43	EC50	3734	nM	CHEMBL1594911

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression	2
Doxorubicin	affects expression	2
Folic Acid	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	affects expression, decreases expression	2
Valproic Acid	decreases expression, affects expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
captax	decreases expression	1
terbufos	increases methylation	1
cinnamaldehyde	decreases expression	1
1,6-hexamethylene diisocyanate	decreases expression	1
sulforaphane	decreases expression	1
ammonium hexachloroplatinate	decreases expression	1
aflatoxin B2	increases methylation	1
7-aminocephalosporanic acid	decreases expression	1
4-aminophenylarsenoxide	decreases reaction, affects binding	1
chloropicrin	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases expression	1
incobotulinumtoxinA	decreases expression	1
(+)-JQ1 compound	increases expression	1
bisphenol AF	decreases expression	1
Resveratrol	increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Acrolein	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, decreases methylation	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1738244	Binding	PUBCHEM_BIOASSAY: Fluorescence-based biochemical high throughput dose response assay for inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF). (Class of assay: confirmatory) [Related pubchem assays (depositor defi	PubChem BioAssay data set

Cellosaurus cell lines

8 cell lines: 7 induced pluripotent stem cell, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A6IY	ZZUNEUi021-A	Induced pluripotent stem cell	Male
CVCL_B0W6	SYSUi005-A	Induced pluripotent stem cell	Male
CVCL_C1TI	YCMi007-A	Induced pluripotent stem cell	Male
CVCL_D6NW	ICSSUi006-A	Induced pluripotent stem cell	Male
CVCL_E0RR	Ubigene HeLa TNNT2 KO	Cancer cell line	Female
CVCL_RM74	UKKi031-A	Induced pluripotent stem cell	Female
CVCL_RM75	UKKi031-B	Induced pluripotent stem cell	Female
CVCL_RM76	UKKi031-C	Induced pluripotent stem cell	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	PHASE4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	PHASE4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	PHASE4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	PHASE4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	PHASE4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	PHASE4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	PHASE4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	PHASE4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	PHASE4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	PHASE4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05718128	PHASE4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	PHASE4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00170183	PHASE3	COMPLETED	Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
NCT00270387	PHASE3	COMPLETED	A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00321295	PHASE3	COMPLETED	Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
NCT00483197	PHASE3	UNKNOWN	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
NCT00490321	PHASE3	UNKNOWN	VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00626028	PHASE3	COMPLETED	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
NCT01013714	PHASE3	UNKNOWN	Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01217827	PHASE3	COMPLETED	Implantable Cardioverter-Defibrillator Use in the VA System
NCT01648634	PHASE3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02924285	PHASE3	COMPLETED	Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease
NCT03860935	PHASE3	COMPLETED	Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT04166331	PHASE3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05175066	PHASE3	COMPLETED	Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT06158698	PHASE3	RECRUITING	CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06563895	PHASE3	RECRUITING	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06846086	PHASE3	RECRUITING	Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
NCT07116473	PHASE3	NOT_YET_RECRUITING	To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT00185250	PHASE2	COMPLETED	Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
NCT00490347	PHASE2	COMPLETED	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
NCT00694161	PHASE2	COMPLETED	The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy